Elexacaftor (VX-445)
$300.00
CAS No.: 2216712-66-0
Catalog No.: 193671
Purity: 95%
MF: C26H34F3N7O4S
MW: 597.664
Storage: 2-8 degree Celsius
SMILES: CN1N=C(C(=C1)S(=O)(=O)NC(C1=C(N=C(C=C1)N1N=C(C=C1)OCC(C(F)(F)F)(C)C)N1C(C[C@@H](C1)C)(C)C)=O)C
Catalog No.: 193671
Purity: 95%
MF: C26H34F3N7O4S
MW: 597.664
Storage: 2-8 degree Celsius
SMILES: CN1N=C(C(=C1)S(=O)(=O)NC(C1=C(N=C(C=C1)N1N=C(C=C1)OCC(C(F)(F)F)(C)C)N1C(C[C@@H](C1)C)(C)C)=O)C
Elexacaftor (VX-445); (S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide; CAS No.: 2216712-66-0; Elexacaftor (VX-445). PROPERTIES: Elexacaftor (VX-445) is a crystalline solid with the molecular formula C25H24F3N3O3. It exhibits good solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety considerations include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 483.48 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms that contribute to its binding affinity and metabolic resistance. Its logP value around 2.9 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: Elexacaftor (VX-445) serves as a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, investigated for the treatment of cystic fibrosis. In clinical research, it is used in combination regimens to enhance CFTR protein function and improve respiratory and gastrointestinal symptoms in patients with specific CFTR mutations. The compound is employed in pharmacokinetic studies to optimize dosing regimens and in mechanism-of-action studies to understand how CFTR correctors restore chloride channel function. Additionally, it functions as a research tool in molecular biology to investigate CFTR protein folding and in drug discovery to explore novel approaches to treating cystic fibrosis. According to "CFTR Modulators: A New Era in Cystic Fibrosis Therapy," Elexacaftor represents a breakthrough in targeted therapy for cystic fibrosis.
Reviews
Write Your Own Review